Amphotericin B administrationAmphotericin B is our first-line anti-fungal agent. Amphotericin B Lipid Complex (Abelcet) may be substituted for amphotericin B if the baby is unable to tolerate amphotericin B or has renal insufficiency. Because of its caustic nature, amphotericin B must be carefully ordered and administered. A separate order form is available for patients who need to receive this drug.
(PICC, BROVIAC® catheter* or UVC) is the preferred route of administration. A peripheral iv can be used if it is the only available access. However, if a peripheral iv is used, the infusion site should be carefully checked every 30 minutes for potential extravasation.
Amphotericin B or Ablecet should be administered over 4 hours.
Amphotericin B is incompatible with most medications and electrolytes and can only be administered in a dextrose solution.
Young TE, Mangrum OB. Neofax 2001: A Manual of Drugs Used in Neonatal Care, 14th ed. Acorn Publishing. pgs. 6 & 9.
Baley JE, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatrics 1990; 116: 791-7.
Kingo AR, Smyth JA, Waisman D. Lack of evidence of amphotericin B toxicity in very low birth weight infants treated for systemic candidiasis. Ped Infect Dis J 1997; 16: 1002-3.
Adler-Shohet F, Waskin H, Lieberman JM. Amphotericin B lipid complex for neonatal invasive candidiasis. Arch Dis Child Fetal & Neonatal Ed 2001; 84: F131-3.
Presented at Clinical Case Review Conference 1/15/02 and approved at Clinical Division Meeting 1/21/02.
* BROVIAC® is a registered trademark of C.R.Bard, Inc. and its related company, BCR, Inc.
Archived Versions: None